Filing Details
- Accession Number:
- 0001127602-13-033700
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-12-04 16:28:38
- Reporting Period:
- 2013-12-02
- Filing Date:
- 2013-12-04
- Accepted Time:
- 2013-12-04 16:28:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1145197 | Insulet Corp | PODD | Surgical & Medical Instruments & Apparatus (3841) | 043523891 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1181286 | T Charles Liamos | C/O Insulet Corporation 9 Oak Park Drive Bedford MA 01730 | Chief Operating Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-12-02 | 19,035 | $4.86 | 137,229 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2013-12-02 | 3,810 | $18.75 | 141,039 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2013-12-02 | 8,000 | $7.06 | 149,039 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2013-12-02 | 4,000 | $14.48 | 153,039 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2013-12-02 | 27,363 | $15.82 | 180,402 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-12-02 | 62,208 | $36.26 | 118,194 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2013-12-03 | 1,600 | $15.82 | 119,794 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-12-03 | 1,600 | $36.00 | 118,194 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2013-12-02 | 19,035 | $0.00 | 19,035 | $4.86 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2013-12-02 | 3,810 | $0.00 | 3,810 | $18.75 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2013-12-02 | 8,000 | $0.00 | 8,000 | $7.06 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2013-12-02 | 4,000 | $0.00 | 4,000 | $14.48 |
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2013-12-02 | 27,363 | $0.00 | 27,363 | $15.82 |
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2013-12-03 | 1,600 | $0.00 | 1,600 | $15.82 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2015-12-09 | No | 4 | M | Direct | |
0 | 2018-05-08 | No | 4 | M | Direct | |
0 | 2019-07-30 | No | 4 | M | Direct | |
0 | 2020-06-01 | No | 4 | M | Direct | |
122,637 | 2021-01-10 | No | 4 | M | Direct | |
121,037 | 2021-01-10 | No | 4 | M | Direct |
Footnotes
- Includes 33,334 restricted stock units granted on January 10, 2011 which vest on December 31, 2013; 24,000 restricted stock units granted on April 1, 2012 which vest one-third of the total units on April 1, 2014, one-third of the total units on April 1, 2015 and one-third of the total units on April 1, 2016; and 30,000 restricted stock units granted on March 1, 2013 which vest one-quarter of the total units on March 1, 2014, one-quarter of the total units on March 1, 2015, one-quarter of the total units on March 1, 2016 and one-quarter of the total units on March 1, 2017. Vested shares will be delivered to the reporting person as soon as practicable following avesting date.
- Includes an aggregate of 960 shares acquired under the Insulet Corporation Amended and Restated 2007 Employee Stock Purchase Plan on the following dates: 357 shares acquired on June 29, 2012; 360 shares acquired on December 31, 2012; and 243 shares acquired on June 28, 2013.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2013.
- The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $35.93 to $37.07. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full informaiton regarding the number of shares sold at each separate price.
- The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $35.97 to $36.01. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full informaiton regarding the number of shares sold at each separate price.
- This option is subject to a three-year vesting period, with 50% of the total award vesting one year after the grant date, 25% of the total award vesting two years after the grant date and 25% of the total award vesting three years after the grant date, subject to continued service as a director or consultant.
- This option is subject to a three-year vesting period with 50% of the total award vesting one year after the grant date, 25% of the total award vesting two years after the grant date and 25% of the total award vesting three years after the grant date, subject to continued service as a director or consultant.
- This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant.
- This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.